Senescent bone marrow mesenchymal stem cells promote multiple myeloma cell proliferation through galectins-3

doi:10.12307/2026.395

Abstract

Abstract: BACKGROUND: Studies showed that multiple myeloma microenvironment has the function of inducing mesenchymal stem cells to become senescent phenotype, while the effect of senescent bone marrow mesenchymal stem cells on multiple myeloma cells is rarely reported.
OBJECTIVE: To investigate the effect of senescent bone marrow mesenchymal stem cells on the proliferation of multiple myeloma cells through paracrine galectin-3.
METHODS: Bone marrow blood was collected from healthy donors, and bone marrow mesenchymal stem cells were extracted by Ficoll density gradient centrifugation and adherent purification. The third-generation bone marrow mesenchymal stem cells were taken and induced with 200 µmol/L hydrogen peroxide solution for 2 hours. After the treatment was completed, they were replaced with L-DMEM complete medium for 24 hours of culture to construct the senescent bone marrow mesenchymal stem cell model. β-Galactosylase staining and senescence gene P21 were used for identification. Meanwhile, the expression of galectin-3 in aging bone marrow mesenchymal stem cells was detected by RT-qPCR. The supernatant of senescent bone marrow mesenchymal stem cells was collected and the conditioned medium of senescent bone marrow mesenchymal stem cells was prepared by centrifugal concentration. After culturing the multiple myeloma cell line U266 for 24 hours with it, the proliferation of U266 cells was detected by CCK-8 assay. The apoptosis of U266 cells was detected by flow cytometry. The expression levels of BCL-2 protein and mRNA in U266 cells were detected by RT-qPCR and western blot assay. Bone marrow blood was collected from patients with multiple myeloma and healthy individuals. The level of galectin-3 was detected by ELISA.
RESULTS AND CONCLUSION: (1) After hydrogen peroxide induction, the number of cells positive for β-galactosidase staining increased significantly, and P21 and galectin-3 mRNA expression levels were upregulated (P < 0.01). (2) Compared with the control group, 24 hours of culture of U266 cells with conditioned medium from senescent bone marrow mesenchymal stem cells increased the level of cell proliferation (P < 0.05), decreased the apoptosis rate (P < 0.05), and rose the expression levels of BCL-2 protein and mRNA (P < 0.05). (3) Galectin-3 levels in the bone marrow of patients with multiple myeloma were significantly higher than those in healthy controls (P < 0.05). These results suggest that senescent bone marrow mesenchymal stem cells may promote the proliferation of multiple myeloma cells by paracrine galectin-3, which in turn upregulates BCL-2 expression.

Key words: senescent, bone marrow mesenchymal stem cell, multiple myeloma, galectin-3, paracrine, bone marrow microenvironment, apoptosis, proliferation

CLC Number:

Fan Tingting, Xiang Miaomiao, Yuan Xiaoshuang, Yang Xu, Yang Bo, Tian Ting, Chen Xiaoxu, Tang Dongxin, Wang Feiqing, Liu Yang, Li Yanju. Senescent bone marrow mesenchymal stem cells promote multiple myeloma cell proliferation through galectins-3[J]. Chinese Journal of Tissue Engineering Research, 2026, 30(19): 4836-4842.

Figures/Tables 5

References

[1] MARLEIN CR, PIDDOCK RE, MISTRY JJ, et al. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Res. 2019;79(9):2285-2297.
[2] COWAN AJ, GREEN DJ, KWOK M, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464-477.
[3] LU Q, YANG D, LI H, et al. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25.
[4] HO M, XIAO A, YI D, et al. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Curr Oncol. 2022;29(11):8975-9005.
[5] WESTER R, SONNEVELD P. Innovations in treatment and response evaluation in multiple myeloma. Haematologica. 2016;101(5):518-520.
[6] DIMOPOULOS MA, MOREAU P, TERPOS E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322.
[7] 石玉士,许家威,刘青青,等.IL-6/IL-6R/JAK2/STAT3通路调控骨髓微环境对多发性骨髓瘤生物学行为影响的研究进展[J].中国实验血液学杂志,2024, 32(1):318-321.
[8] GUO J, ZHAO Y, FEI C, et al. Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis. 2018; 9(5):512.
[9] ANDRÉ T, MEULEMAN N, STAMATOPOULOS B, et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 2013;8(3):e59756.
[10] CHOI H, KIM Y, KANG D, et al. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma. Cell Prolif. 2020;53(5):e12819.
[11] COPPÉ JP, DESPREZ PY, KRTOLICA A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.
[12] PLAKHOVA N, PANAGOPOULOS V, VANDYKE K, et al. Mesenchymal stromal cell senescence in haematological malignancies. Cancer Metastasis Rev. 2023; 42(1):277-296.
[13] DI GH, LIU Y, LU Y, et al. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 2014;9(11):e113572.
[14] FUKUMORI T, KANAYAMA HO, RAZ A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat. 2007;10(3):101-108.
[15] RUVOLO PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016;1863(3):427-437.
[16] FAIRFIELD H, DUDAKOVIC A, KHATIB CM, et al. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype. Cancer Res. 2021;81(3):634-647.
[17] LI Y, XU X, WANG L, et al. Senescent mesenchymal stem cells promote colorectal cancer cells growth via galectin-3 expression. Cell Biosci. 2015;5:21.
[18] 徐飞,郑泽航,徐汉青,等.过氧化氢诱导小鼠骨髓间充质干细胞衰老细胞模型的建立[J].中南医学科学杂志,2021,49(2):129-132.
[19] 张弛可,王飞清,吴丹,等.急性髓系白血病细胞条件培养液对间充质干细胞的生物学影响[J].中国组织工程研究,2024,28(31):4995-5002.
[20] 刘洋,吴晓冰,荆永,等.过氧化氢诱导间充质干细胞衰老模型的建立[J].军事医学,2015,39(5):329-333.
[21] 段长伟,柴彦杰,赵疆东,等.骨髓间充质干细胞分离与培养技术[J].宁夏医学杂志,2021,43(6):573-576.
[22] AKHTAR S, ALI TA, FAIYAZ A, et al. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma. Int J Mol Sci. 2020;21(14): 5002.
[23] BERGFELD SA, DECLERCK YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010;29(2):249-261.
[24] NATONI A, BOHARA R, PANDIT A, et al. Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment. Front Bioeng Biotechnol. 2019;7:252.
[25] ZHANG G, MIAO F, XU J, et al. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13. Bosn J Basic Med Sci. 2020;20(2):209-217.
[26] NOLL JE, WILLIAMS SA, TONG CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163-171.
[27] MONDELLO P, CUZZOCREA S, NAVARRA M, et al. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget. 2017;8(12):20394-20409.
[28] ZHENG MM, ZHANG Z, BEMIS K, et al. The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One. 2013;8(3):e58504.
[29] FAIRFIELD H, COSTA S, FALANK C, et al. Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes. Front Oncol. 2021;10:584683.
[30] PLAKHOVA N, PANAGOPOULOS V, VANDYKE K, et al. Mesenchymal stromal cell senescence in haematological malignancies. Cancer Metastasis Rev. 2023; 42(1):277-296.
[31] ÖZDEMIR A, ŞIMAY DEMIR YD, YEŞILYURT ZE, et al. Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy. Adv Protein Chem Struct Biol. 2023;133:115-158.
[32] WOŚ J, SZYMAŃSKA A, LEHMAN N, et al. Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia? Cells. 2023;13(1):30.
[33] HARAZONO Y, NAKAJIMA K, RAZ A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev. 2014;33(1):285-294.
[34] 田堃.P38 MAPK参与调节人脐带间充质干细胞对人白血病肿瘤细胞的生长抑制[D].北京:北京协和医学院,2011.
[35] 邱纪玲,王晓彤,周灏雯,等.间充质干细胞条件培养液修复多种疾病损伤的潜能[J].中国组织工程研究,2019,23(29):4743-4748.